Why 7 of the Highest-Yielding ‘Strong Buy' Health Care Stocks Are the Absolute Best 2023 Buys24/7 Wall Street • 04/12/23
April MDA Breakout Stocks/ETFs Week 15 - 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 04/09/23
5 Recession-Proof Stocks With High Cash, Low Debt, Strong Dividends To Protect Your Portfolio In 2023Benzinga • 04/07/23
Merck and Eisai report disappointing results from trials of combination treatment for melanoma and colorectal cancerMarket Watch • 04/07/23
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)Business Wire • 04/07/23
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV MelanAccesswire • 04/06/23
3 Reasons to Buy Healthcare Stocks in the Current Market EnvironmentZacks Investment Research • 04/06/23
FDA Approves Merck's KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial CancerBusiness Wire • 04/03/23
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27Business Wire • 03/30/23
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid TumorsBusiness Wire • 03/29/23
Merck Stock Today: How A Bear Call Spread Can Return 10% In Less Than One MonthInvestors Business Daily • 03/29/23
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair StatusBusiness Wire • 03/27/23
Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)Business Wire • 03/27/23